Charles Gaulin/providers.dartmouth-health.org
Charles Gaulin, Hematologic Oncologist and Assistant Professor of Medicine at Dartmouth Hitchcock Medical Center and Clinics, shared a post on LinkedIn:
“At ASH25, Chad Markey presented our retrospective study on the impact of preexisting mental health disorders and psychiatric pharmacotherapy in immune effector cell therapy recipients.
Prolonged LOS: The presence of pre-existing Mental Health Disorders (MHDs) was independently associated with a prolonged hospital LOS.
Protective Effect: Patients who were receiving psychiatric pharmacotherapy had a shorter LOS, comparable to those without psychiatric comorbidity, suggesting a potential protective effect of proactive management.
Highest LOS: In our grouped model, patients with MHDs who were not receiving pharmacotherapy had the longest estimated LOS.
No significant differences were observed between MHD and non-MHD patients in CRS or ICANS, response rates, or overall survival.
These results highlight the need for proactive psychiatric assessment and management to optimize hospitalization outcomes for patients receiving immune effector cell therapies.
Authors: Chad Markey, William Patterson, Jaini Shah, Martha Lodyga, Todd MacKenzie, Sivan Rotenberg, Hirotaka Miyashita, MD, PhD, Ivy Riano, M.D., Parth Shah, Brian Rosen, Frederick (Erick) Lansigan, Charles Gaulin
Read the full abstract.”
More updates from ASH25.